此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

每日一次缓释药物治疗的肾移植受者中测量的他克莫司 C:D 比率 (TaC:Drop)

2026年11月3日 更新者:Edward Geissler

多中心、开放标签、随机、双组、平行组、评估两种每日一次他克莫司制剂的生物利用度和实用性的优越性试验,Envarsus® 与 Advagraf™ 相比,在肾移植受者中使用

The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.

研究概览

地位

主动,不招人

条件

详细说明

This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability.

The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time.

Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters.

Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.

研究类型

介入性

注册 (实际的)

322

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Aachen、德国、52074
        • University Hospital Aachen, Department of General, Visceral and Transplant Surgery
      • Berlin、德国、10117
        • Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
      • Bochum、德国、44892
        • Knappschaft Clinic, University Hospital Bochum, Department of Surgery
      • Dresden、德国、01307
        • University Hospital Dresden, Division of Nephrology
      • Hamburg、德国、20251
        • University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
      • Hanover、德国、30625
        • Hannover Medical School, Department of General, Visceral and Transplant Surgery
      • Jena、德国、07747
        • University Hospital Jena, Internal Medicine III, Nephrology
      • Mainz、德国、55131
        • University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
      • Mannheim、德国、68167
        • University Hospital Mannheim, Medical Clinic V
      • Munich、德国、81377
        • LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
      • Münster、德国、48149
        • University Hospital Münster, Medical Clinic D
      • Regensburg、德国、93053
        • University Hospital Regensburg, Department of Nephrology
      • Würzburg、德国、97080
        • University Hospital Würzburg, Medical Clinic I, Department of Nephrology

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Signed and dated written informed consent
  2. Adult (≥18 years old) male or female
  3. Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor
  4. ABO blood type compatible with the donor kidney
  5. Able to swallow an oral formulation of tacrolimus in tablet or capsule form

Exclusion Criteria:

  1. Multi-organ transplantation
  2. Any previous solid organ transplantation (other than a first kidney allograft)
  3. For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease
  4. Patient and/or donor is positive for active HCV, HBV or HIV infection
  5. History of any malignancy that could not be curatively treated
  6. Ongoing abuse of drugs or alcohol
  7. Signs of advanced liver disease or any signs of liver decompensation
  8. Ongoing uncontrolled systemic infection
  9. Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
  10. Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™
  11. Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides
  12. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  13. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception
  14. Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period
  15. Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
  16. Inability to freely give informed consent (e.g. individuals under legal guardianship)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Envarsus

Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

其他名称:
  • 恩华苏斯
有源比较器:Advagraf

Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

其他名称:
  • Advagraf

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)
大体时间:12 weeks after kidney transplantation

To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory.

12 weeks after kidney transplantation

次要结果测量

结果测量
措施说明
大体时间
谷值低于、低于或高于目标范围的患者比例
大体时间:肾移植后4天、14天、28天、12周
肾移植后4天、14天、28天、12周
平均他克莫司谷水平和他克莫司谷水平的患者间变异性(范围)
大体时间:肾移植后4天、14天、28天、12周
肾移植后4天、14天、28天、12周
他克莫司的平均每日剂量和他克莫司每日剂量的患者间变异性(范围)
大体时间:肾移植后4天、14天、28天、12周
肾移植后4天、14天、28天、12周
C/D 比和每日剂量的患者内部变异性
大体时间:测量时间点:第 4 天、第 14 天、第 28 天和第 12 周
测量时间点:第 4 天、第 14 天、第 28 天和第 12 周
有因活检的发生率
大体时间:肾移植后12周
肾移植后12周
需要治疗的急性排斥反应的发生率
大体时间:肾移植后12周
肾移植后12周
活检证实的急性排斥反应的类固醇耐药事件的发生率
大体时间:肾移植后12周和1年
肾移植后12周和1年
CMV 和 BKV 感染的发生率(包括器官表现,如果相关)
大体时间:肾移植后12周和1年
肾移植后12周和1年
不良反应(AR)的发生率、类型、严重性和严重性
大体时间:肾移植后 12 周和 3 年
肾移植后 12 周和 3 年
血压
大体时间:肾移植后12周和1、2、3年
肾移植后12周和1、2、3年
需要诊断检查的胃肠道疾病的发生率
大体时间:肾移植后 12 周和 3 年
肾移植后 12 周和 3 年
原发性肾脏疾病复发
大体时间:肾移植后 12 周和 3 年
肾移植后 12 周和 3 年
新发 DSA 的发生率
大体时间:肾移植后第一年内发现
肾移植后第一年内发现
糖皮质激素治疗的剂量和持续时间
大体时间:肾移植后12周和1、2、3年
肾移植后12周和1、2、3年
研究停止治疗的发生率和时间
大体时间:肾移植后3年
肾移植后3年
患者退出研究的发生率、时间和原因
大体时间:肾移植后3年
肾移植后3年
Time to reach the first trough level in target range
大体时间:Time period measured in days, assessed within the first 2 weeks after kidney transplantation

Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading

Time period measured in days, assessed within the first 2 weeks after kidney transplantation
Tacrolimus concentration/dose (C/D) ratio
大体时间:4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation

The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site.

4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
Treatment failure rate
大体时间:12 weeks and 1, 2, 3 years after kidney transplantation

A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause)

12 weeks and 1, 2, 3 years after kidney transplantation
Time to treatment failure after transplantation
大体时间:Measured until 3 years after kidney transplantation

Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause)

Measured until 3 years after kidney transplantation
Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection
大体时间:12 weeks and 1, 2, 3 years after kidney transplantation

Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition.

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of graft failure
大体时间:12 weeks and 1, 2, 3 years after kidney transplantation

Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation

12 weeks and 1, 2, 3 years after kidney transplantation
Mortality rate
大体时间:12 weeks and 1, 2, 3 years after kidney transplantation

Mortality rate measures death from any cause

12 weeks and 1, 2, 3 years after kidney transplantation
Graft function measured by eGFR (estimated glomerular filtration rate)
大体时间:4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation

eGFR calculated according to the CKD-EPI formula

4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of delayed graft function
大体时间:Measurable within the first 2 weeks after kidney transplantation

Delayed graft function is defined as the need for more than one episode of dialysis after transplantation

Measurable within the first 2 weeks after kidney transplantation
Incidence rate of primary non-function of the renal allograft
大体时间:Measurable within the first 12 weeks after kidney transplantation

Primary non-function is defined as the necessity for ongoing chronic dialysis

Measurable within the first 12 weeks after kidney transplantation
Incidence of hepatotoxicity
大体时间:12 weeks and 1, 2, 3 years after kidney transplantation

Hepatotoxicity is defined as GPT or GOT levels ≥ 2.5 x upper limit of normal range

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence of de novo tremor
大体时间:12 weeks and 3 years after kidney transplantation

Incidence and severity of tremor based on medical assessment by the investigator

12 weeks and 3 years after kidney transplantation
Incidence of new onset diabetes mellitus after transplantation (NODAT)
大体时间:12 weeks and 1, 2, 3 years after kidney transplantation

NODAT is defined as HbA1c ≥ 6.5% or 47.5 mmol/mol or fasting plasma glucose ≥ 126 mg/dl on two separate occasions

12 weeks and 1, 2, 3 years after kidney transplantation
Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34)
大体时间:12 weeks and 3 years after kidney transplantation

The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients.

12 weeks and 3 years after kidney transplantation
Dose of mycophenolate
大体时间:12 weeks and 1, 2, 3 years after kidney transplantation

Including both mycophenolate mofetil and mycophenolic acid

12 weeks and 1, 2, 3 years after kidney transplantation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Bernhard Banas, MD、University Hospital Regensburg

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年3月9日

初级完成 (实际的)

2026年2月4日

研究完成 (估计的)

2028年11月1日

研究注册日期

首次提交

2024年2月12日

首先提交符合 QC 标准的

2024年2月12日

首次发布 (实际的)

2024年2月20日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • TaC:Drop
  • 2023-503531-18-00 (其他标识符:EUCT Number)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅